{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-271189","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.744907+00:00","generated_at":"2026-05-16T23:08:07.167461+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Xilio reports 40% ORR in MSS mCRC with high plasma TMB; advances masked T cell engager programs","bullets":["Vilastobart + atezolizumab: 40% ORR in heavily pre-treated MSS mCRC without liver mets and high plasma TMB (≥10 mut/Mb); p=0.05 correlation.","Estimated 55% of MSS CRC patients have high plasma TMB via Guardant360 assay, vs <10% by tissue TMB.","Preclinical masked T cell engagers show reduced systemic toxicity and enhanced durability with costimulation; PSMA candidate nominated Q3 2025.","Phase 1 efarindodekin alfa: well-tolerated at >100-fold MTD of rhIL-12, 2 PRs in advanced solid tumors, immune infiltration.","Vilastobart ctDNA data: deep reductions associated with response; 2 patients achieved endoscopic CR with undetectable ctDNA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-271189","json":"https://secwatch.observer/filing/0001193125-25-271189.json","markdown":"https://secwatch.observer/filing/0001193125-25-271189.md","text":"https://secwatch.observer/filing/0001193125-25-271189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525271189/0001193125-25-271189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525271189/xlo-20251107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:08:07.167461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}